CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel

Summary

Dual antiplatelet therapy with clopidogrel and aspirin has been the standard of care in the United States for patients with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary interventions (PCI). However, the effectiveness of clopidogrel varies significantly among different sub-populations due to inter-individual variability. In this study we examined the antiplatelet potential of a novel mixed disulfide conjugate of clopidogrel with the aim to overcome the inter-individual variability. In the metabolic studies using human liver microsomes and cDNA-expressed P450s, we confirmed that multiple P450s are involved in the bioactivation of 2-oxoclopidogrel to H4, one of the diastereomers of the pharmacologically active metabolite (AM) possessing antiplatelet activity. Results from kinetic studies demonstrated that 2C19 is the most active in converting 2-oxoclopidogrel to H4 with a catalytic efficiency of 0.027 µM^-1min^-1 in the reconstituted system. On the basis of this finding, we were able to biosynthesise the conjugate of clopidogrel with 3-nitropyridine-2-thiol, referred to as clopNPT, and examined its antiplatelet activity in male New Zealand white rabbits. After administration as intravenous bolus at 2 mg/kg, the clopNPT conjugate was rapidly converted to the AM leading to the inhibition of platelet aggregation (IPA). Analyses of the blood samples drawn at various time points showed that intravenous administration of clopNPT led to ~70% IPA within 1 hour and the IPA persisted for more than 3 hours. Since the antiplatelet activity of clopNPT does not require bioactivation by P450s, the mixed disulfide conjugate of clopidogrel has the potential to overcome the inter-individual variability in clopidogrel therapy.

Keywords

Clopidogrel - antiplatelet - mixed disulfide conjugate - inter-individual variability - active metabolite

• References

• 1 King SB 3rd, Smith SC Jr,, Hirshfeld JW Jr,. et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation 2008; 117: 261-295.
• 2 Yusuf S, Mehta SR, Zhao F. et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966-972.
• 3 Gurbel PA, Tantry US. Clopidogrel resistance?. Thromb Res 2007; 120: 311-321.
• 4 Guha S, Mookerjee S, Guha P. et al. Antiplatelet drug resistance in patients with recurrent acute coronary syndrome undergoing conservative management. Indian Heart J 2009; 61: 348-352.
• 5 Kwan J, Htun WW, Huang Y. et al. Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in chinese patients with percutaneous coronary intervention. Vasc Health Risk Manag 2011; 07: 399-404.
• 6 Hulot JS, Bura A, Villard E. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
• 7 Shuldiner AR, O’Connell JR, Bliden KP. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
• 8 Mega JL, Close SL, Wiviott SD. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
• 9 Savi P, Combalbert J, Gaich C. et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. Thromb Haemost 1994; 72: 313-317.
• 10 Savi P, Pereillo JM, Uzabiaga MF. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
• 11 Kazui M, Nishiya Y, Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
• 12 Dansette PM, Bertho G, Mansuy D. First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives. Biochem Biophys Res Commun 2005; 338: 450-455.
• 13 Dansette PM, Rosi J, Bertho G. et al. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 2012; 25: 348-356.
• 14 Dansette PM, Thebault S, Bertho G. et al. Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel. Chem Res Toxicol 2010; 23: 1268-1274.
• 15 Zhang H, Lau WC, Hollenberg PF. Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes. Mol Pharmacol 2012; 82: 302-309.
• 16 Savi P, Herbert JM, Pflieger AM. et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-532.
• 17 Bluet G, Blankenstaein J, Brohan E. et al. Synthesis of the stablized active meta-bolite of clopidogrel. Tetrahedron Lett 2014; 70: 3893-3900.
• 18 Tuffal G, Roy S, Lavisse M. et al. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 2011; 105: 696-705.
• 19 Zhang H, Lauver DA, Lucchesi BR. et al. Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel. Mol Pharmacol 2013; 83: 848-856.
• 20 Zhang H, Sridar C, Kenaan C. et al. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: A charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome P450-reductase complex. J Pharmacol Exp Thera 2011; 338: 803-809.
• 21 Shan J, Zhang B, Zhu Y. et al. Overcoming clopidogrel resistance: Discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. J Med Chem 2012; 55: 3342-3352.
• 22 Lauver DA, Kaissarian NM, Lucchesi BR. Oral pretreatment with liposomal glutathione attenuates reperfusion injury in rabbit isolated hearts. J Cardiovasc Pharmacol 2013; 61: 233-239.
• 23 Meister A, Anderson ME. Glutathione. Ann Rev Biochem 1983; 52: 711-760.
• 24 Hagihara K, Kazui M, Kurihara A. et al. Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate. Drug Metab Dispos 2012; 40: 1854-1859.
• 25 Hagihara K, Kazui M, Kurihara A. et al. Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyri-dine antiplatelet agent, prasugrel. Drug Metab Dispos 2011; 39: 208-214.
• 26 Guengerich FP. Human cytochrome P450 enzyme. In Cytochrome P450: Structure, mechanism, and biochemistry. Plenum; New York: 1995. pp 473-535.
• 27 Zhu Y, Zhou J. Identification of the significant involvement and mechanistic role of CYP3A4/5 in clopidogrel bioactivation. ACS Med Chem Lett 2012; 03: 844-849.
• 28 Zhu Y, Zhou J. In vitro biotransformation studies of 2-oxo-clopidogrel: Multiple thiolactone ring-opening pathways further attenuate prodrug activation. Chem Res Toxicol 2013; 26: 179-190.
• 29 Caplain H, Donat F, Gaud C. et al. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999; 25 (Suppl. 02) 25-28.
• 30 Cadroy Y, Bossavy JP, Thalamas C. et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823-2828.
• 31 Farid NA, Kurihara A, Wrington SA. Metabolism and disposition of thienopyri-dine antiplatelet drugs ticlopidone, clopidogrel and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-142.
• 32 Silvain J, Montalescot G. Rapid P2Y12 inhibition: Still an unmet medical need. Circ Cardiovasc Interv 2012; 05: 328-331.
• 33 Alexopoulos D, Xanthopoulou I, Gkizas V. et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 05: 797-804.
• 34 Parodi G, Valenti R, Bellandi B. et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: Rapid (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.